Issue link: https://www.e-digitaleditions.com/i/1500880
News on R&D and progress in the treatment of respiratory diseases, such as asthma and COPD. Calendar: The industry organizations page of the Inhalation website provides descriptions and contact information for cross-industry organizations and groups that present educational conferences and workshops. 34 June 2023 Inhalation were classified as RSV infected or not infected in the first year of life. Of those, 54% were infected with RSV. Participants were followed prospectively for five years and then evaluated for 5-year current asthma. Results demonstrated that infants who were not infected with RSV in the first year of life had a 26% lower risk of asthma at 5 years of age than those who were infected with RSV as infants. e NIAID news release explained that because the study was obser- vational, the results did not defini- tively establish causality. However, it noted, the results support a need for long-term follow-up of common respiratory outcomes among children in clinical trials of RSV-prevention products. Results were published in e Lancet. CALENDAR Please visit the industry organi- zations page of the Inhalation website to find descriptions and contact information for cross- industry organizations and groups that present educational confer- ences and workshops. https://www.inhalationmag.com/ industry-organizations Aerosol School 2023. Aerosol School is being offered virtually for 2023 and is now available for viewing. Led by Professor Myrna Dolovich, industry, academic and clinical experts offer information and training in the measurements of medical aerosols for industry or clinical research. e program is sponsored by ISAM, St. Joseph's Healthcare and the McMaster University Firestone Institute for Respiratory Health's (FIRH). Reg- ister online at www.aerosolschool. com or by emailing mdolovic@ mcmaster.ca. Mycobacterium tuberculosis bacte- ria combined with GLA-SE, an immune-stimulating adjuvant. e National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), sup- ported a recent Phase 1 study that investigated whether administer- ing a freeze-dried, thermostable formulation of the vaccine con- taining both ID93 and GLA-SE in a single vial would be as effective at inducing an immune response as a regimen in which non-thermo- stable ID93 and liquid GLA-SE are held in two vials and com- bined prior to injection. Both vac- cine presentations were safe and well-tolerated by healthy adults. e researchers concluded the results were "a proof-of-concept that adjuvant-containing vaccines can be formulated in a freeze- dried single-vial presentation without detrimentally impacting clinical immunogenicity or safety characteristics." NIAID indicated that thermostable vaccines are desirable in settings where main- taining cold or frozen vaccines for long periods can be costly and dif- ficult. e researchers also noted that a single-vial option would have advantages in ease of storage as well as transport and adminis- tration. Results were published in Nature Communications. Study increases evidence linking RSV and childhood asthma BETHESDA, MARYLAND— e National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), announced findings of the NIAID-supported study, Infant Susceptibility to Pulmonary Infec- tions and Asthma Following RSV Exposure (INSPIRE). It is the first cohort specifically designed to test the hypothesis that not being infected with respiratory syncytial virus (RSV) in infancy decreases the risk of childhood asthma. e study included 1,946 healthy infants, 1,741 of whom shape information. e company also provides laboratory analyz- ers that measure particle size and shape, sulfur in oil, fluorescence spectroscopy, Raman imaging and spectroscopy, glow discharge opti- cal emission spectrometry and ICP-OES spectrometers. Pari acquires Nortev, manufacturer of equine inhaler STARNBERG, GERMANY AND MIDLOTHIAN, VIRGINIA— Pari has announced its acquisition of Nortev, which manufactures and sells the Flexineb® E3, a nebulizer that provides respiratory therapy in horses by medication or saline, according to a news release jointly issued by the two companies. Nortev also offers nebulization devices for companion animals and distributes its products to more than 30 countries in Europe, North America, Australia and the Middle East. Nortev will continue to be run as an independent company and there will be no changes for its Flexineb customers as a result of the acquisition. e takeover of Nortev is the first acquisition under PARI's growth and diversi- fication strategy, the news release noted. PARI's goal is to establish their inhalation therapy experience in the field of animal inhalation. With Nortev, they plan to develop new inhalation therapies that ben- efit horses and small animals with respiratory diseases and, in turn, benefit their owners. RESPIRATORY MEDICINE NEWS Experimental thermostable TB vaccine formulated in a single vial BETHESDA, MARYLAND— e experimental tuberculo- sis (TB) vaccine ID93+GLA-SE is a recombinant subunit vac- cine made from four proteins of INDUSTRY NEWS continued from page 8